AXIM Biotechnologies, Inc. (AXIM)
OTCMKTS: AXIM · Delayed Price · USD
0.0150
+0.0001 (0.67%)
Jul 26, 2024, 4:00 PM EDT - Market closed
AXIM Biotechnologies Employees
As of December 31, 2023, AXIM Biotechnologies had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees decreased by 2 or -22.22% compared to the previous year.
Employees
7
Change (1Y)
-2
Growth (1Y)
-22.22%
Revenue / Employee
$12,193
Profits / Employee
-$798,479
Market Cap
4.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
AXIM News
- 4 months ago - VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024 - GlobeNewsWire
- 5 months ago - AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation - GlobeNewsWire
- 7 months ago - AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production - GlobeNewsWire
- 11 months ago - AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson's Disease - Business Wire
- 1 year ago - AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test - Business Wire
- 1 year ago - Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide - GlobeNewsWire
- 1 year ago - AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide - GlobeNewsWire
- 1 year ago - AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch - GlobeNewsWire